Related Experiment Video
Updated: Apr 24, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Mdm2 and MdmX involvement in human cancer
1Biochemistry and Molecular Biology, Wright State University, 3640 Colonel Glenn Hwy, Dayton, OH, 45435, USA, steven.berberich@wright.edu.
Abstract:
Discovered in 1987 and 1997 respectively, Mdm2 and MdmX represent two critical cellular regulators of the p53 tumor suppressor. This chapter reviews each from initial discovery to our current understanding of their deregulation in human cancer with a focus on how each regulator impacts p53 function. While p53 independent activities of Mdm2 and MdmX are noted the reader is directed to other reviews on this topic. The chapter concludes with an examination of the various mechanisms of Mdm-deregulation and an assessment of the current therapeutic approaches to target Mdm2 and MdmX overexpression.
Insights
Mdm2 and MdmX are key regulators of the p53 tumor suppressor. This review covers their discovery, role in cancer, and therapeutic targeting strategies for Mdm2 and MdmX overexpression.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Mdm2 and MdmX are crucial regulators of the p53 tumor suppressor protein.
- Deregulation of Mdm2 and MdmX is implicated in human cancer development.
- Understanding their impact on p53 function is vital for cancer research.
Purpose of the Study:
- To review the discovery and evolving understanding of Mdm2 and MdmX.
- To analyze the mechanisms of Mdm2 and MdmX deregulation in cancer.
- To assess current therapeutic strategies targeting Mdm2 and MdmX.
Main Methods:
- Literature review of Mdm2 and MdmX research.
- Analysis of Mdm2 and MdmX roles in p53 regulation.
- Examination of cancer-associated deregulation mechanisms.
- Assessment of therapeutic approaches.
Main Results:
- Mdm2 and MdmX play critical roles in controlling p53 activity.
- Their deregulation is a common feature in various human cancers.
- Targeting Mdm2 and MdmX presents a promising therapeutic avenue.
Conclusions:
- Mdm2 and MdmX are central to p53 regulation and cancer biology.
- Further research into Mdm-deregulation mechanisms can inform novel therapies.
- Targeting Mdm2 and MdmX overexpression offers potential for cancer treatment.
Related Concept Videos
Abnormal Proliferation
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Mismatch Repair
Mitogens and the Cell Cycle
Induced Pluripotent Stem Cells
Somatic...

